Vir Biotechnology Inc (VIR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.71B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vir Biotechnology Inc (VIR) Stock Forecast
Analysts expect Vir Biotechnology (VIR) to earn -$1.00 per share in the fiscal year ending Dec 31, 2026, on revenue of $330.33M. Of 9 analysts, 9 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 33.3% |
| Buy | 6 | 66.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 79.8%.
- Fiscal year ending Dec 31, 2026
- -$1.00
- EPS consensus, revenue $330.33M
- Fiscal year ending Dec 31, 2027
- -$2.39
- EPS consensus, revenue $66.74M
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.00 | -$1.75 to -$0.07 | 8 | $330.33M | $238.80M to $543.72M | 8 |
| Dec 31, 2027 | -$2.39 | -$2.84 to -$1.92 | 7 | $66.74M | $2.00M to $156.75M | 7 |
Quarterly Estimates
The EPS consensus rises from -$0.53 for the quarter ending Dec 31, 2026 to -$0.44 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.53 | -$0.71 to -$0.10 | 10 | $28.83M | $1.96M to $69.09M | 8 |
| Mar 31, 2027 | -$0.44 | -$0.66 to -$0.31 | 4 | $17.00M | $500000 to $50.01M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.78.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.00 | -$1.77 | -$1.76 | -$1.76 | -$1.78 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.39 | -$2.47 | -$2.49 | -$2.49 | -$2.49 | N/A |
| Quarter ending Mar 31, 2027 | -$0.44 | -$0.49 | -$0.43 | -$0.43 | -$0.47 | N/A |
Frequently Asked Questions About VIR
What is the VIR stock forecast?
Consensus analyst estimates put Vir Biotechnology's EPS at -$1.00 for the fiscal year ending Dec 31, 2026, on revenue of $330.33M. The consensus rating from 9 analysts is Buy.
How do analysts rate VIR stock?
Of 9 analysts covering Vir Biotechnology, 3 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VIR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.00, with estimates from -$1.75 to -$0.07 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.39, with estimates from -$2.84 to -$1.92 from 7 analysts.
What revenue do analysts expect from Vir Biotechnology next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $330.33M, with estimates from $238.80M to $543.72M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $66.74M, with estimates from $2.00M to $156.75M.
How many analysts cover VIR?
9 analysts rate Vir Biotechnology stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
VIR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts